financetom
Business
financetom
/
Business
/
MongoDB Q3 Non-GAAP Earnings, Revenue Increase; Fiscal 2025 Outlook Raised -- Shares Jump After Hours
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
MongoDB Q3 Non-GAAP Earnings, Revenue Increase; Fiscal 2025 Outlook Raised -- Shares Jump After Hours
Dec 9, 2024 2:01 PM

04:32 PM EST, 12/09/2024 (MT Newswires) -- MongoDB ( MDB ) reported Q3 non-GAAP earnings late Monday of $1.16 per diluted share, up from $0.96 a year earlier.

Analysts polled by FactSet expected $0.68.

Revenue for the quarter ended Oct. 31 was $529.4 million, up from $432.9 million a year earlier.

Analysts surveyed by FactSet expected $497.2 million.

The company said it expects Q4 non-GAAP EPS between $0.62 and $0.65 and revenue between $515 million and $519 million. Analysts polled by FactSet expect $0.56 and $507.8 million, respectively.

The company expects fiscal 2025 non-GAAP EPS between $3.01 and $3.03 and revenue between $1.97 billion and $1.98 billion. The company previously expected non-GAAP EPS of $2.33 to $2.47 and revenue of $1.92 billion to $1.93 billion. Analysts surveyed by FactSet expect non-GAAP EPS of $2.43 and revenue of $1.94 billion.

Shares of the company jumped past 10% in recent after-hours activity.

Price: 385.99, Change: +35.86, Percent Change: +10.24

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
InflaRx Anti-Inflammatory Drug Chosen for Phase 2 Acute Respiratory Distress Syndrome Trial; Shares Rise
InflaRx Anti-Inflammatory Drug Chosen for Phase 2 Acute Respiratory Distress Syndrome Trial; Shares Rise
Jun 24, 2024
11:19 AM EDT, 06/24/2024 (MT Newswires) -- InflaRx ( IFRX ) said Monday that the Biomedical Advanced Research and Development Authority has selected its anti-inflammatory drug Gohibic, or vilobelimab, for a Phase 2 clinical trial evaluating options to treat acute respiratory distress syndrome. The trial, expected to start later this year, will assess 600 hospitalized adults and the primary endpoint...
Chevron forecasts second-quarter production impact
Chevron forecasts second-quarter production impact
Jun 24, 2024
June 24 (Reuters) - Energy major Chevron ( CVX ) said on Monday it expects upstream turnarounds and downtime to impact 65,000 barrels of oil equivalent per day in production in the second quarter mostly driven by Tengizchevroil in Kazakhstan and several Gulf of Mexico assets. (Reporting by Sourasis Bose in Bengaluru) ...
--Lead Real Estate to Pay Special Cash Dividend Sept. 30 to Shareholders of Record June 30
--Lead Real Estate to Pay Special Cash Dividend Sept. 30 to Shareholders of Record June 30
Jun 24, 2024
11:17 AM EDT, 06/24/2024 (MT Newswires) -- Price: 7.23, Change: -1.47, Percent Change: -16.90 ...
Mexico's America Movil acquires dominant interest in ClaroVTR
Mexico's America Movil acquires dominant interest in ClaroVTR
Jun 24, 2024
June 24 (Reuters) - Mexico's America Movil, controlled by the family of billionaire Carlos Slim, acquired a dominant stake in cable and mobile phone operator ClaroVTR, which had been shared equally with Liberty Latin America ( LILA ) , America Movil and LLA said on Monday. The Mexican telecommunications giant will transform the convertible notes it holds in ClaroVTR into...
Copyright 2023-2026 - www.financetom.com All Rights Reserved